cabozantinib

Ligand id: 5887

Name: cabozantinib

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: cabozantinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 98.78
Molecular weight 501.17
XLogP 5.79
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

References
1. Abou-Alfa GK, Meyer T, Cheng A-L, El-Khoueiry A, Rimassa L, Ryoo B-Y, Cicin I, Merle P, Chen Y-H, Park J-W et al.. (2018)
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.
Journal of Clinical Oncology, 36 (15 (suppl)): 4019. DOI: 10.1200/JCO.2018.36.15_suppl.4019
2. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K et al.. (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
N. Engl. J. Med., 373 (19): 1814-23. [PMID:26406150]
3. FDA. 
FDA grants regular approval to Cabometyx for first-line treatment of advanced renal cell carcinoma.
Accessed on 03/01/2018. Modified on 03/01/2018. fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589842.htm?utm_campaign=Oncology%2012%2F20&utm_medium=email&utm_source=Eloqua&elqTrackId=9bc32150b77e4929b686ed8a82ffbb6e&elq=70477587f45543ad83873a1367bab364&elqaid=1850&elqat=1&elqCampaignId=1227
4. Rimassa L, Cicin I, Blanc J-F, Klümpen HJ, Zagonel V, Tran A, Kim SCH, Lin Z-Z, Tam VC, Hazara S et al.. (2018)
Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).
Jout=rnal of Clonical Oncology, 36 (15 (suppl)): 4090. DOI: 10.1200/JCO.2018.36.15_suppl.4090
5. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B et al.. (2011)
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Mol. Cancer Ther., 10 (12): 2298-308. [PMID:21926191]